
SENATE CONCURRENT RESOLUTION

REQUESTING THE AUDITOR TO ASSESS THE SOCIAL AND FINANCIAL
EFFECTS OF MANDATORY HEALTH INSURANCE COVERAGE FOR
BIOMARKER TESTING.

1 WHEREAS, biomarker testing is an invaluable tool in the
2 diagnosis, treatment, appropriate management, and ongoing
3 monitoring of diseases or conditions; and
4

5 WHEREAS, biomarker testing is the analysis of a patient's
6 tissue, blood, or other biospecimen for the presence of a
7 biomarker, a type of precision medicine that looks for genes,
8 proteins, and other substances that can provide information
9 about a patient's chronic condition; and
10

11 WHEREAS, biomarker testing allows for a more precise and
12 personalized approach to medical care by identifying specific
13 genetic, molecular, or biochemical markers associated with an
14 individual's disease; and
15

16 WHEREAS, biomarker testing enables health care providers to
17 tailor treatments based on the unique characteristics of
18 a patient's condition, leading to more effective and targeted
19 interventions; and
20

21 WHEREAS, despite the fact that biomarker testing is
22 essential to high-quality, personalized care to treat serious
23 illness and enhance patients' quality of life, patients cannot
24 easily access it; and
25

26 WHEREAS, H.B. No. 1971 (2026) requires insurers, mutual
27 benefit societies, health maintenance organizations, and health
28 plans under the State's Medicaid managed care program to provide
29 coverage for biomarker testing for the purposes of diagnosis,
30 treatment, appropriate management, or ongoing monitoring of a



1 person's disease or condition to guide treatment decisions when
2 supported by medical and scientific evidence; and

3
4 WHEREAS, pursuant to section 23-51, Hawaii Revised
5 Statutes, "[b]efore any legislative measure that mandates health
6 insurance coverage for specific health services, specific
7 diseases, or certain providers of health care services as part
8 of individual or group health insurance policies, can be
9 considered, concurrent resolutions shall be passed that
10 designate a specific legislative bill for the Auditor to review
11 and prepare a report for submission to the Legislature that
12 assesses both the social and financial effects of the proposed
13 mandated coverage" under that legislative bill; and

14
15 WHEREAS, section 23-52, Hawaii Revised Statutes, further
16 specifies the minimum information required for assessing the
17 social and financial impact of the proposed health coverage
18 mandate in the Auditor's report; now, therefore,

19
20 BE IT RESOLVED by the Senate of the Thirty-third
21 Legislature of the State of Hawaii, Regular Session of 2026, the
22 House of Representatives concurring, that the Auditor is
23 requested to assess, in accordance with sections 23-51 and
24 23-52, Hawaii Revised Statutes, the social and financial effects
25 of mandating health insurance coverage for biomarker testing for
26 the purposes of diagnosis, treatment, appropriate management, or
27 ongoing monitoring of a person's disease or condition, or to
28 guide treatment decisions when supported by medical and
29 scientific evidence, as provided in H.B. No. 1971 (2026); and

30
31 BE IT FURTHER RESOLVED that the Auditor is requested to
32 submit a report of the Auditor's findings and recommendations,
33 including any proposed legislation, to the Legislature no later
34 than twenty days prior to the convening of the Regular Session
35 of 2027; and

36
37 BE IT FURTHER RESOLVED that certified copies of this
38 Concurrent Resolution be transmitted to the Auditor, Director of
39 Commerce and Consumer Affairs, and Insurance Commissioner.

